Loading
A phase 1/2 trial of Pembrolizumab, Lenvatinib and Favezelimab in small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) is a phase 1/2 interventional study registered as NCT04938817 by Merck Sharp & Dohme LLC, with 110 participants enrolled, started 2021-08-19 and due to reach its primary completion in 2029-12-10. Interventions recorded: coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830, coformulation favezelimab/pembrolizumab and R-DXd.
Shares Favezelimab, Lenvatinib, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
Shares Favezelimab, Lenvatinib, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
Shares Favezelimab, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Merck & Co. (MSD), Small-cell lung cancer, Pembrolizumab and the tag pipeline.
Shares Lenvatinib, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Lenvatinib, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.